US EditionPublished • loading... • Updated
Health Canada approves 1st pill to treat postpartum depression
Zuranolone offers rapid relief from moderate to severe postpartum depression, improving symptoms within three days as confirmed by clinical trials involving 196 women, Health Canada said.
- Health Canada has approved the first drug designed to treat postpartum depression, a pill called Zuranolone to be taken for 14 days.
- Zuranolone acts quickly, relieving depressive symptoms in as few as three days, unlike other antidepressants which take longer.
- Postpartum depression can cause severe symptoms like depressed mood, anxiety, irritability, fatigue and difficulty bonding with the baby.
Insights by Ground AI
42 Articles
42 Articles
Postpartum depression drug zuranolone approved by Health Canada
Health Canada has approved the first drug designed to treat postpartum depression. The regulator says zuranolone, a pill sold under the brand name Zurzuvae, is authorized in Canada to relieve symptoms of moderate or severe depression after childbirth.
·Canada
Read Full Article
Health Canada approved the first drug designed to treat postpartum depression. Zuranolone can relieve symptoms within three days.
·Montreal, Canada
Read Full Article
Zuranolone can relieve depressive symptoms in just a few days.
·Montreal, Canada
Read Full Article
Winnipeg Free Press+32 Reposted by 32 other sources
Health Canada approves 1st pill to treat postpartum depression
Breaking News, Sports, Manitoba, Canada
·Winnipeg, Canada
Read Full Article
Coverage Details
Total News Sources42
Leaning Left20Leaning Right0Center7Last UpdatedBias Distribution74% Left
Bias Distribution
- 74% of the sources lean Left
74% Left
L 74%
C 26%
Factuality
To view factuality data please Upgrade to Premium
